title: Psoralens percutaneous permeation across the human whole skin and the epidermis in respect to their polarity (in vitro study).
abstract: 8-methoxypsoralen (8-MOP), 5-methoxypsoralen (5-MOP) and 4,5',8-trimethylpsoralen (TMP) are commonly used in PUVA therapy [psoralen (P) + ultraviolet light A (UVA) irradiation] to treat skin diseases such as psoriasis and vitiligo. In order to predict the choice of the suitable drug(s) for topical applications, with appropriate dosage, percutaneous permeation of the psoralens, in connection with their solubilities and partition coefficients in an octanol/water system, were investigated. The percutaneous penetration experiments were accomplished by the deposit of ethanolic psoralen solution onto human skin and epidermis fragments mounted on Franz cells. Six cells were employed for each psoralen solution and for the whole skin layer as well as for the epidermis. The diffused psoralens in the receptor solution (1.4%, of human serum albumin) were quantified by using high performance liquid chromatography. The solubilities and the partition coefficients (PC) were carried out in an octanol/water system, in triplicate by using spectrofluorimetry. The results demonstrated that cumulated permeated quantities (ng/cm2) over 24 h, across the whole skin and the epidermis were in the following order for the three psoralens: 8-MOP > 5-MOP > TMP. The lipophilicity, expressed via the log PC, was as follows: 1.93 +/- 0.01 (8-MOP), 2.00 +/- 0.01 (5-MOP) and 3.14 +/- 0.01 (TMP). It was inversely correlated with cumulated penetrated amounts over 24 h in both whole skin and epidermis. From these results, TMP could be predicted as the most convenient psoralen for topical applications, because of its weak penetrability. Considering the relationship between psoralens lipophilicity and permeation, only 5-MOP and 8-MOP could be used, topically or orally, especially in the case of generalised skin disorders.
authors.affiliation: Laboratoire de Pharmacie Galenique, Faculte de Medecine et de Pharmacie, Besancon, France.
authors.forename: A
authors.initials: A
authors.lastname: Saïd
authors.forename: S
authors.initials: S
authors.lastname: Makki
authors.forename: P
authors.initials: P
authors.lastname: Muret
authors.forename: P
authors.initials: P
authors.lastname: Humbert
authors.forename: J
authors.initials: J
authors.lastname: Millet
mesh_terms: D000078223:5-Methoxypsoralen; D000287:Administration, Topical; D004817:Epidermis / Q000378:metabolism; D005260:Female; D011564:Furocoumarins / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D006801:Humans; D066298:In Vitro Techniques; D008730:Methoxsalen / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D011701:PUVA Therapy; D010539:Permeability; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D012867:Skin / Q000378:metabolism*; D012995:Solubility; D014307:Trioxsalen / Q000493:pharmacokinetics
chemical_list: D011564:Furocoumarins; D017319:Photosensitizing Agents; D000078223:5-Methoxypsoralen; D008730:Methoxsalen; D014307:Trioxsalen